
|Slideshows|November 7, 2014
The Surgeon General vs the Marlboro Man: Who Really Won?
Author(s)Alan Blum, MD
The images in this slide set are from an exhibition curated by Alan Blum, MD, at the University of Alabama Gorgas Library (November to December 2013) to commemorate the 50th anniversary of the Surgeon General’s Report on Smoking and Health, released on January 11, 1964 by Dr. Luther Terry.
Advertisement
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement


130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
BySara M. Tolaney, MD, MPH,Evandro de Azambuja,Kevin Kalinsky, MD, MS,Sherene Loi, MD, PhD,Sung-Bae Kim,Clinton Yam,Bernardo Rapoport, MD,Seock-Ah Im,Barbara Pistilli,Wassim McHayleh,David W. Cescon,Junichiro Watanabe,Manuel Alejandro Lara Banuelas,Ruffo Freitas-Junior,Javier Salvador Bofill,Maryam Afshari,Dianna Gary,Lu Wang,Catherine Lai, MD, MPH,Peter Schmid, MD



Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
How Effective and Safe is EUS-Guided Alpha DaRT in Pancreatic Cancer?
2
Cevostamab May Fill Gap in Multiple Myeloma Armamentarium
3
131 Primary Results From ASCENT-03: A Randomized Phase 3 Study of Sacituzumab Govitecan (SG) vs Chemotherapy (Chemo) in Patients (pts) With Previously Untreated Advanced Triple-Negative Breast Cancer (TNBC) Who Are Unable to Receive PD-(L)1 Inhibitors (PD-[L]1i)
4
ASCO Updates 340B Policy Statement to Expand Access, Improve Transparency
5













































